View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, June 6 (HealthDay News) -- The melanocyte-keratinocyte transplantation procedure (MKTP) is well tolerated and is effective for restoring skin pigmentation for some patients with vitiligo, according to a study published in the May issue of the Journal of the American Academy of Dermatology.
Richard H. Huggins, M.D., of the Henry Ford Hospital in Detroit, and colleagues conducted a prospective, uncontrolled, open-label study involving 28 patients aged 18 years or older with a self-reported history of vitiligo and no new or expanding lesions for at least six months before surgery. The participants underwent a total of 36 MKTP procedures. Repigmentation was assessed during a three- to six-month follow-up period.
The researchers found that the three- and six-month follow-up was completed by 23 patients who underwent 29 procedures. Of these, repigmentation was excellent in 17 percent, good in 31 percent, fair in 10 percent, and poor in 41 percent. Average improvement was −45 percent in the Vitiligo Area Scoring Index, which is indicative of improved pigmentation.
"The results achieved in our study were of obvious significance to our patients," a coauthor said in a statement. "We believe this new treatment option offers hope to patients of color and those with vitiligo on one side of the body or in one area of the body."
Several of the authors disclosed financial ties to the pharmaceutical industry.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top